DOI: http://dx.doi.org/10.18203/2349-3933.ijam20211062

Idelalisib induced drug toxicity presenting as drug induced pneumonitis: a case report

Sameer Verma, Dhwani Pandya, Sameer Khanijo, Michael Esposito, Arunabh Talwar

Abstract


Idelalisib is a novel treatment option for patients with chronic lymphocytic leukemia. A rare, but, fatal complication of using Idelalsib is drug induced pneumonitis. This article presents a case of Idelalsib induced pneumonitis in a patient with chronic lymphocytic leukemia along with a brief discussion of management plan.


Keywords


Idelalisib, Chornic lymphocytic leukemia, Drug induced interstitial lung diseases, Phosphatidylinositol 3 kinase inhibitor, Steroids

Full Text:

PDF

References


Travis WD, Costabel U, Hansell DM. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733-48.

Erasmus JJ, McAdams HP, Rossi SE. Drug-induced lung injury. Semin Roentgenol 2002;37:72-81.

Ripley BA KT, Gill RR. Deciphering drug-induced interstitial lung disease: A mechanistic approach Appl Radiol. 2016;45:9-18.

Matsuno O. Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res. 2012;13:39.

Cleverley JR, Screaton NJ, Hiorns MP, Flint JD, Muller NL. Drug-induced lung disease: high-resolution CT and histological findings. Clin Radiol. 2002;57:292-9.

Skeoch S, Weatherley N, Swift AJ. Drug-Induced Interstitial Lung Disease: A Systematic Review. J Clin Med. 2018;7.

Pietra GG. Pathologic mechanisms of drug-induced lung disorders. J Thorac Imaging. 1991;6:1-7.

Schwaiblmair M, Behr W, Haeckel T, Markl B, Foerg W, Berghaus T. Drug induced interstitial lung disease. Open Respir Med J. 2012;6:63-74.

Simpson AB, Paul J, Graham J, Kaye SB. Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours. Br J Cancer. 1998;78:1061-6.

Mendez JL, Nadrous HF, Hartman TE, Ryu JH. Chronic nitrofurantoin-induced lung disease. Mayo Clin Proc 2005;80:1298-302.

Reinert T BC, Nunes FAP, Scheliga AAdS. Bleomycin-Induced Lung Injury. Journal of Cancer Research. 2013;2013:9.

Crimi E, Sica V, Williams-Ignarro S. The role of oxidative stress in adult critical care. Free Radic Biol Med. 2006;40:398-406.

Miyakoshi S, Kami M, Yuji K. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood. 2006;107:3492-4.

Ohri A, Arena FP. Severe pulmonary complications in African-American patient after bortezomib therapy. Am J Ther. 2006;13:553-5.

Suissa S, Hudson M, Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum. 2006;54:1435-9.

Miwa Y, Isozaki T, Wakabayashi K. Tacrolimus-induced lung injury in a rheumatoid arthritis patient with interstitial pneumonitis. Mod Rheumatol. 2008;18:208-11.

Sleijfer S, van der Mark TW, Schraffordt Koops H, Mulder NH. Enhanced effects of bleomycin on pulmonary function disturbances in patients with decreased renal function due to cisplatin. Eur J Cancer. 1996;32A:550-2.

Oya N, Sasai K, Tachiiri S. Influence of radiation dose rate and lung dose on interstitial pneumonitis after fractionated total body irradiation: acute parotitis may predict interstitial pneumonitis. Int J Hematol. 2006;83:86-91.

Yang Q, Modi P, Newcomb T, Queva C, Gandhi V. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma. Clin Cancer Res. 2015;21:1537-42.

Fruman DA, Cantley LC. Idelalisib--a PI3Kdelta inhibitor for B-cell cancers. N Engl J Med. 2014;370:1061-2.

Coutre SE, Barrientos JC, Brown JR. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015;56:2779-86.

Drug statistical FDA. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206545lbl.pdf. Accessed 10 August 2020.

Chuzi S, Tavora F, Cruz M. Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. Cancer Manag Res 2017;9:207-13.

Vulisha AK, Talwar A, Verma S, Gupta A, Lam L. Nivolumab Induced Toxicity Presenting As Pneumonitis- A Case Report. J Pulm Respir Med 2018;8.